The Down Under medical community is abuzz with the arrival of retatrutide, a novel dual GIP and GLP-1 receptor showing significant results in clinical trials for treating obesity. This therapy suggests a https://socialistener.com/story7233549/the-new-retatrutide-australia-a-emerging-prospect-for-weight-management